Imagine a virus that acts like a wildfire through pig farms and forests, where current medicines just don't work. This team is creating a 'weakened' version of the virus that teaches the animal's immune system to fight the real thing without making them sick. They are even designing special baits so wild boars can be vaccinated in the woods without needing a vet.
African Swine Fever causes devastating losses in pig populations and triggers expensive trade bans. Current vaccines are either unsafe or ineffective, and there is no way to vaccinate wild boar populations that act as disease reservoirs.
A set of live attenuated vaccine candidates, specifically ASFV-G-ΔI177L, and a strategy for oral bait delivery for wildlife.
If you are a vaccine manufacturer dealing with the lack of a global ASF vaccine — this project developed the ASFV-G-ΔI177L candidate that shows high protective efficacy. This allows for the creation of licensed products for both domestic pigs and wild boar.
If you are a farm operator dealing with trade bans and costly control measures due to ASF outbreaks — this project developed a vaccine strategy that reduces viral loads and prevents shedding. This helps safeguard animal health and maintains market access.
If you are a wildlife agency dealing with the inability to control disease in abundant wild boar populations — this project developed oral bait vaccines. This provides a tool to stop the virus from spreading from the wild back into domestic farms.
Based on available project data, the specific unit cost or market price of the vaccine is not mentioned.
The project includes 2 industry partners and focuses on translating lab results into field strategies, suggesting a path toward industrial scale, though specific production volumes are not listed.
The project aims to develop licensed vaccines and involves regulators from the start to ensure data is used for benefit-risk assessments for licensure.
The project follows international guidelines for safety and efficacy tests to generate the database required by authorities for licensure.
The project period runs from 2024-01-01 to 2026-12-31, focusing on generating the data needed for licensure during this window.
The consortium is heavily weighted toward research and academia, with 5 research institutes and 1 university. However, the inclusion of 2 industry partners (18% ratio) and 3 other organizations across 8 countries indicates a strong push toward commercialization and regulatory alignment, led by the Friedrich Loeffler Institut.
Contact the Friedrich Loeffler Institut (FLI) in Germany
Contact us to explore licensing opportunities for the ASFV-G-ΔI177L vaccine candidate.
